Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of AK160 in Patients With Dupuytren's Contracture

Next Previous
Trial Profile

Phase III Study of AK160 in Patients With Dupuytren's Contracture

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 03 Jul 2015 Asahi Kasei Pharma Corporation has received approval for manufacture and sale of collagenase clostridium histolyticum [XIAFLEX] for the treatment of Dupuytren's contracture in Japan, according to media release.
  • 31 Jul 2014 Asahi Kasei Pharma Corporation has completed a regulatory submission for XIAFLEX for Dupuytren's contracture in Japan, and a PMDA review is expteced to be completed by mid 2015, according to an Auxilium Pharmaceuticals media release.
  • 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top